// App-Quantinova.ai

LBA4001 : Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.

Researchers

Presenter

  • Ian Chau

Principal Investigators

  • Jaffer A. Ajani

  • Jianming Xu

  • Lucjan Wyrwicz

  • Satoru Motoyama

  • Takashi Ogata

  • Hisato Kawakami

  • Chih-Hung Hsu

  • Antoine Adenis

  • Farid El Hajbi

  • Maria Di Bartolomeo

  • Maria Ignez Freitas Melro Braghiroli

  • Eva Holtved

  • Ioannis Xynos

  • Xuan Liu

  • Ming Lei

  • Kaoru Kondo

  • Ken Kato

  • Yuko Kitagawa

Medical Centers

  • Royal Marsden Hospital, Surrey, United Kingdom

  • Osaka University Graduate School of Medicine, Suita, Japan

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China

  • Klinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warsaw, Poland

  • Akita University, Akita, Japan

  • Kanagawa Cancer Center, Yokohama, Japan

  • Kinki University Faculty of Medicine, Osaka, Japan

  • National Taiwan University Hospital, Taipei, Taiwan, Institut du Cancer de Montpellier, Montpellier, France

  • Centre Oscar Lambret, Lille, France

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Institute of Cancer of São Paolo, University of São Paolo, São Paolo, Brazil

  • Odense University Hospital, Odense, Denmark

  • Bristol Myers Squibb, Princeton, NJ, Department of Head and Neck Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

Locations

  • United Kingdom

  • Japan

  • China

  • Poland

  • France

  • Italy

  • Brazil

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal squamous carcinoma cell

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Fluorouracil

  • Adrucil injection

  • Ipilimumab

  • Nivolumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT03143153

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved